Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Tonix Pharmaceuticals Holding (TNXP) Change in Account Payables (2017 - 2026)

Tonix Pharmaceuticals Holding has reported Change in Account Payables over the past 4 years, most recently at $1.5 million for Q1 2026.

For Q1 2026, Change in Account Payables rose 534.28% year-over-year to $1.5 million; the TTM value through Mar 2026 reached $4.9 million, up 303.16%, while the annual FY2025 figure was $3.0 million, 222.98% up from the prior year.
Change in Account Payables for Q1 2026 was $1.5 million at Tonix Pharmaceuticals Holding, up from -$738000.0 in the prior quarter.
Over five years, Change in Account Payables peaked at $3.7 million in Q2 2024 and troughed at -$6.4 million in Q3 2024.
A 4-year average of $151076.9 and a median of $581000.0 in 2024 define the central range for Change in Account Payables.
Biggest five-year swings in Change in Account Payables: plummeted 725.07% in 2024 and later skyrocketed 534.28% in 2026.
Year by year, Change in Account Payables stood at -$3.9 million in 2023, then soared by 114.76% to $581000.0 in 2024, then plummeted by 227.02% to -$738000.0 in 2025, then surged by 307.72% to $1.5 million in 2026.
Business Quant data shows Change in Account Payables for TNXP at $1.5 million in Q1 2026, -$738000.0 in Q4 2025, and $1.0 million in Q3 2025.